Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pelthos Therapeutics (PTHS) Current Deferred Revenue (2025)

Pelthos Therapeutics has reported Current Deferred Revenue over the past 1 years, most recently at $966000.0 for Q4 2025.

  • Quarterly results put Current Deferred Revenue at $966000.0 for Q4 2025, changed N/A from a year ago — trailing twelve months through Dec 2025 was $966000.0 (changed N/A YoY), and the annual figure for FY2025 was $966000.0, changed.
  • Current Deferred Revenue for Q4 2025 was $966000.0 at Pelthos Therapeutics, down from $1.0 million in the prior quarter.
  • Over the last five years, Current Deferred Revenue for PTHS hit a ceiling of $1.0 million in Q3 2025 and a floor of $966000.0 in Q4 2025.